EN DE
Watch Singapore Institute of Advance for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Singapore Institute of Advance (9G2) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Singapore Institute of Advance stock S$0.03, price S$0.03, that is 1.0% below the price, quality 27 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SGXE79544776

SI Singapore Institute of Advance logo Thin data Nov 16, 2026

Singapore Institute of Advance

9G2 · SG

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value 0.0267 SGD · Fairly valued 
Revenue last quarter 12% below a year ago. 
Quality 27/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −1.1 %/yr in SGD) 
Loss-making · -152.0% net margin (TTM) 
Negative free cash flow 
Trails peers (2/10) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Singapore Institute of Advance for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.1900 SGD 0.0200 SGD Fair Value 0.0267 SGD Feb 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

33‑month range 0.0200 SGD – 0.1900 SGD · fair‑value band 0.0250 SGD – 0.0285 SGD · the 0.0270 SGD price screens above the 0.0267 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Singapore Institute of Advance in your weekly email

Every Wednesday you see whether Singapore Institute of Advance is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Singapore Institute of Advanced Medicine Holdings Ltd., an investment holding company, provides medical diagnostics and treatments, and radiation therapy and medical oncology services in Singapore.

Show moreShow less

The company offers medical diagnostics and treatments, including cancer-related diagnostics and theragnostic treatments, general diagnostics and health screening, and aesthetic services; and radiation therapy and medical oncology services comprise proton beam therapy, photon radiation therapy, and medical oncology services.

It provides clinic and imaging services; manufactures medical research and clinical diagnostic instruments and supplies; and sells pharmaceuticals, surgical products, and consumables. Singapore Institute of Advanced Medicine Holdings Ltd. was incorporated in 2011 and is based in Singapore.

Stock analysis

Singapore Institute of Advance (9G2) currently trades at 0.0270 SGD, while our estimate is 0.0267 SGD, so the stock looks roughly fairly valued today (gap 1.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 0.0250 SGD (bear) to 0.0285 SGD (bull), the price of 0.0270 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Singapore Institute of Advance reported revenue of 15.7M SGD in FY2026 versus 13.8M SGD in FY2022, a compound +3.3%/yr. Reported net income was −23.9M SGD in FY2026.

Key figures

Market cap 46.6M SGD (≈ $36.1M) Micro · P/S ratio 2.19 · EPS (TTM) −0.0200 SGD · Return on equity −44.0% · Return on assets (EBIT) −12.9% (5-year average) · Operating margin −152% · Revenue (TTM) 15.7M SGD · Revenue growth (YoY) −11.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −1%, 9G2 screens cheaper than that median.

Fair Value

Bear 0.0250 SGD Fair Value 0.0267 SGD Bull 0.0285 SGD
Price 0.0270 SGD · Downside -1.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 59
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 89
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−96.4% (2022) → −128.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch 9G2, get fair value alerts →

Compare Singapore Institute of Advance with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −1.1% · Below median
Profitability
Return on assets −18.1% · Bottom 25%
Net margin (12 months) −152.0% · Bottom 25%
Operating margin (12 months) −151.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −11.9% · Bottom 25%
Balance sheet
Debt / equity 0.21× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.88× · Cheapest 25%
P/S (12 months) 2.96× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)32 · sector 33
FUTURE (revenue growth)0 · sector 33
PAST (return on equity)0 · sector 32
HEALTH (low debt)90 · sector 90
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 9G2
DaVita Inc DVA $174.56 $218.90 +25% vs 9G2
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 9G2
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 9G2
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 9G2
The Ensign Group ENSG $188.41 $140.09 −26% vs 9G2
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 9G2
Fresenius SE FRE €53.62 €34.77 −35% vs 9G2
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 9G2
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 9G2

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Singapore Institute of Advance: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Singapore Institute of Advance Fair Value". https://www.fairvalue-calculator.com/stock/9G2

Frequently asked questions

Is Singapore Institute of Advance (9G2) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 0.0267 SGD versus a price of 0.0270 SGD, about 1% lower (fairly valued).
What is the fair value of 9G2?
Our estimate for Singapore Institute of Advance is 0.0267 SGD (as of Nov 16, 2026), built from audited fundamentals. The current price: 0.0270 SGD.
What is the quality score of 9G2?
Singapore Institute of Advance has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Singapore Institute of Advance (9G2)?
Our calculated price target is the estimate of 0.0267 SGD (as of Nov 16, 2026). Cautious scenario 0.0250 SGD, optimistic scenario 0.0285 SGD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Singapore Institute of Advance stock forecast for 2026?
Our estimate puts fair value at 0.0267 SGD, about 1% lower versus a price of 0.0270 SGD (fairly valued). Cautious scenario 0.0250 SGD, optimistic scenario 0.0285 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of Singapore Institute of Advance (9G2)?
Singapore Institute of Advance reported trailing-twelve-month revenue of about 15.7M SGD (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Singapore Institute of Advance (9G2)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Singapore Institute of Advance it is 0.0267 SGD per share (as of Nov 16, 2026), against a price of 0.0270 SGD.
Is Singapore Institute of Advance stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 9G2 trades above its calculated fair value: price 0.0270 SGD, fair value 0.0267 SGD, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9G2?
No. The price is what the market pays today (0.0270 SGD); the fair value is what the company's own numbers justify (0.0267 SGD). For Singapore Institute of Advance the two are 0.0003 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is Singapore Institute of Advance worth?
The market values Singapore Institute of Advance at about 46.6M SGD (market capitalisation, as of Nov 16, 2026). Per share that is 0.0270 SGD; our models calculate a fair value of 0.0267 SGD per share.
What do the bullish and bearish scenarios say about 9G2?
Our models span a range for Singapore Institute of Advance: cautious scenario 0.0250 SGD, base 0.0267 SGD, optimistic 0.0285 SGD per share (as of Nov 16, 2026, price 0.0270 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Singapore Institute of Advance (9G2)?
Balance-sheet figures for Singapore Institute of Advance (as of Nov 16, 2026): return on equity −44.0%, debt of 0.21 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 9G2 from its 52-week high?
Singapore Institute of Advance trades at 0.0270 SGD, about 66% below its 52-week high of 0.0800 SGD and 35% above the low of 0.0200 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0267 SGD is for.
Which stocks are comparable to Singapore Institute of Advance?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Singapore Institute of Advance stock attractive at the current price?
The data as of Nov 16, 2026: price 0.0270 SGD, calculated fair value 0.0267 SGD (−1%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Singapore Institute of Advance itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Singapore Institute of Advance (9G2)?
The closing price on Nov 16, 2026 was 0.0270 SGD. Our estimate is 0.0267 SGD, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Singapore Institute of Advance right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (0.0250 SGD to 0.0285 SGD), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Singapore Institute of Advance

How large is the market capitalisation of Singapore Institute of Advance (9G2)?
The market capitalisation of Singapore Institute of Advance is 46.6M SGD (≈ $36.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Singapore Institute of Advance (9G2)?
The price-to-sales ratio of Singapore Institute of Advance is 2.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Singapore Institute of Advance (9G2)?
Earnings per share at Singapore Institute of Advance are −0.0200 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Singapore Institute of Advance (9G2)?
The return on equity (ROE) of Singapore Institute of Advance is −44.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Singapore Institute of Advance (9G2)?
On an EBIT basis the return on assets of Singapore Institute of Advance is −12.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Singapore Institute of Advance (9G2)?
The operating margin of Singapore Institute of Advance is −152% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Singapore Institute of Advance (9G2)?
Revenue at Singapore Institute of Advance is down 11.9% versus a year earlier (3y avg −1.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Singapore Institute of Advance (9G2) generate?
The free cash flow of Singapore Institute of Advance is −4.1M SGD (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Singapore Institute of Advance (9G2) carry?
The net debt of Singapore Institute of Advance is 14.5M SGD (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Singapore Institute of Advance in the live analysis

One click puts Singapore Institute of Advance on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.